157 related articles for article (PubMed ID: 8384030)
1. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders.
Gearhart MO; Sorg TB
Ann Pharmacother; 1993 Mar; 27(3):285-9. PubMed ID: 8384030
[TBL] [Abstract][Full Text] [Related]
2. Acid-base and electrolyte abnormalities due to capreomycin.
Darr M; Hamburger S; Ellerbeck E
South Med J; 1982 May; 75(5):627-8. PubMed ID: 6177055
[TBL] [Abstract][Full Text] [Related]
3. A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.
Huycke MM; Naguib MT; Stroemmel MM; Blick K; Monti K; Martin-Munley S; Kaufman C
Antimicrob Agents Chemother; 2000 Aug; 44(8):2143-8. PubMed ID: 10898688
[TBL] [Abstract][Full Text] [Related]
4. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
Arch Intern Med; 1995 Jan; 155(1):65-74. PubMed ID: 7802522
[TBL] [Abstract][Full Text] [Related]
5. Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet.
Ota R; Hirata A
J Chemother; 2021 Dec; 33(8):539-546. PubMed ID: 34060436
[TBL] [Abstract][Full Text] [Related]
6. Foscarnet-induced electrolyte abnormalities in a bone marrow transplant patient receiving parenteral nutrition.
Matarese LE; Speerhas R; Seidner DL; Steiger E
JPEN J Parenter Enteral Nutr; 2000; 24(3):170-3. PubMed ID: 10850943
[TBL] [Abstract][Full Text] [Related]
7. Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit.
Buckley MS; Leblanc JM; Cawley MJ
Crit Care Med; 2010 Jun; 38(6 Suppl):S253-64. PubMed ID: 20502178
[TBL] [Abstract][Full Text] [Related]
8. A protocol for foscarnet administration.
Smith DG; Handy CM
J Intraven Nurs; 1992; 15(5):274-7. PubMed ID: 1336798
[TBL] [Abstract][Full Text] [Related]
9. Foscarnet-induced hypokalaemia.
Malin A; Miller RF
J Infect; 1992 Nov; 25(3):329-30. PubMed ID: 1335467
[No Abstract] [Full Text] [Related]
10. Minimising the dosage-limiting toxicities of foscarnet induction therapy.
Jayaweera DT
Drug Saf; 1997 Apr; 16(4):258-66. PubMed ID: 9113493
[TBL] [Abstract][Full Text] [Related]
11. [Systemic cytomegalovirus infection: changes in serum calcium and magnesium levels with foscarnet treatment].
Marzal-Alfaro MB; Manrique-Rodríguez S; Alcaraz Romero A; García San Prudencio M; Fernández-Llamazares CM
An Pediatr (Barc); 2015 Jan; 82(1):e170-4. PubMed ID: 24785445
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy.
Jayaweera D; White G; Moreno J
Genitourin Med; 1995 Dec; 71(6):414-5. PubMed ID: 8566991
[No Abstract] [Full Text] [Related]
13. Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following reduced-intensity cord blood transplantation.
Narimatsu H; Kami M; Kato D; Matsumura T; Murashige N; Kusumi E; Yuji K; Hori A; Shibata T; Masuoka K; Wake A; Miyakoshi S; Morinaga S; Taniguchi S
Transpl Infect Dis; 2007 Mar; 9(1):11-5. PubMed ID: 17313465
[TBL] [Abstract][Full Text] [Related]
14. [Hypocalcemia, hypomagnesemia and hypokalemia induced by capreomycin].
Arrizabalaga P; Domingo M; Montoliu J; Botey A; Revert L
Med Clin (Barc); 1983 Mar; 80(9):413-5. PubMed ID: 6190050
[No Abstract] [Full Text] [Related]
15. Proton-pump Inhibitor-induced Severe Hypomagnesemia and Hypocalcemia are Clinically Masked by Thiazide Diuretic.
Uehara A; Kita Y; Sumi H; Shibagaki Y
Intern Med; 2019 Aug; 58(15):2201-2205. PubMed ID: 30996187
[TBL] [Abstract][Full Text] [Related]
16. Hypomagnesemic hypokalemia and hypocalcemia: clinical and laboratory characteristics.
Elisaf M; Milionis H; Siamopoulos KC
Miner Electrolyte Metab; 1997; 23(2):105-12. PubMed ID: 9252977
[TBL] [Abstract][Full Text] [Related]
17. Neurologic sequelae associated with foscarnet therapy.
Lor E; Liu YQ
Ann Pharmacother; 1994 Sep; 28(9):1035-7. PubMed ID: 7803878
[TBL] [Abstract][Full Text] [Related]
18. Foscarnet treatment in various cytomegalovirus infections.
Brockmeyer NH; Hengge UR; Mertins L; Malessa R; Steinmetz R; Gooss M
Int J Clin Pharmacol Ther Toxicol; 1993 Apr; 31(4):204-7. PubMed ID: 8388868
[TBL] [Abstract][Full Text] [Related]
19. Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures.
Fan-Harvard P; Sanchorawala V; Oh J; Moser EM; Smith SP
Ann Pharmacother; 1994; 28(7-8):869-72. PubMed ID: 7949502
[TBL] [Abstract][Full Text] [Related]
20. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia.
Wazny LD; Brophy DF
Ann Pharmacother; 2000 Jan; 34(1):94-7. PubMed ID: 10669191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
